SAN DIEGO, May 4, 2015 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) today announced that Dr.
Bill Aurora has joined the company
as Vice President, Medical Affairs.
"We are very pleased to welcome Dr. Bill
Aurora to the Neurocrine team as our Vice President, Medical
Affairs," said Kevin Gorman,
President and Chief Executive Officer of Neurocrine Biosciences.
"Bill's experience in medical affairs and scientific exchange and
outreach coupled with his extensive network and influence with
psychiatric and neurological physicians will be of utmost
importance as we evolve into a commercial organization."
Prior to joining Neurocrine, Dr. Aurora was Vice President,
Global Center for Scientific Affairs at Merck. Prior to Merck, he
spent twelve years at Amgen most recently as the Vice President of
Global Scientific Affairs where he lead the Regional Medical
Liaisons, Medical Communications, Medical Information, Medical
Writing, and Scientific Affairs Training and Development groups
across therapeutic areas and geographies. Bill has also held
positions at Novartis and Bristol Myers Squibb. Bill received his
B.S. in Pharmacy from the University of Texas
at Austin, his Doctor of Pharmacy and Clinical Residency in
Psychopharmacy from the University of
Texas Health Science Center at San
Antonio. He is also Board Certified in Psychiatric Pharmacy
Practice (BCPP).
Neurocrine also announced the grant of an inducement award to
Dr. Aurora pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
In connection with his employment with Neurocrine, Dr. Aurora was
granted an inducement award consisting of a stock option to
purchase 60,000 shares of Neurocrine common stock. The stock option
will vest over a period of four years, with 25% vesting on the
first anniversary of the grant date and the balance vesting each
month over the remaining three years. Dr. Aurora also received
25,000 restricted stock units which vest in full after three years
of continuous service. These awards are subject to the terms and
conditions of Neurocrine's Inducement Plan. These awards were
effective on May 1, 2015, the first
business day of the first calendar month following the commencement
of his employment with Neurocrine, and the stock option has an
exercise price of $35.51 per share,
which was the closing price of Neurocrine's common stock on the
NASDAQ Global Select Market on that date. The award was granted as
an inducement material to Dr. Aurora's employment pursuant to Rule
5635(c)(4) of the NASDAQ Listing Rules.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine
transporter 2 inhibitor for the treatment of movement disorders.
Neurocrine intends to maintain certain commercial rights to its
VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company. Neurocrine Biosciences, Inc. news
releases are available through the Company's website via the
internet at http://www.neurocrine.com.
In addition to historical facts, this press release may
contain forward-looking statements that involve a number of risks
and uncertainties. Among the factors that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks that regulatory submissions
may not occur or be submitted in a timely manner; risks that our
product candidates may not obtain regulatory approval or may be
precluded from commercialization by the proprietary rights of third
parties; and other risks described in the Company's quarterly
report on Form 10-Q for the quarter ended March 31, 2015. Neurocrine disclaims any
obligation to update the statements contained in this press release
after the date hereof.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-inc-announces-appointment-of-dr-bill-aurora-as-vice-president-medical-affairs-300076948.html
SOURCE Neurocrine Biosciences, Inc.